Viking Other Operating Expenses vs Total Other Income Expense Net Analysis

VKTX Stock  USD 52.94  1.57  2.88%   
Viking Therapeutics financial indicator trend analysis is much more than just breaking down Viking Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viking Therapeutics is a good investment. Please check the relationship between Viking Therapeutics Other Operating Expenses and its Total Other Income Expense Net accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Other Operating Expenses vs Total Other Income Expense Net

Other Operating Expenses vs Total Other Income Expense Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viking Therapeutics Other Operating Expenses account and Total Other Income Expense Net. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Viking Therapeutics' Other Operating Expenses and Total Other Income Expense Net is 0.46. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Viking Therapeutics, assuming nothing else is changed. The correlation between historical values of Viking Therapeutics' Other Operating Expenses and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Viking Therapeutics are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Other Operating Expenses i.e., Viking Therapeutics' Other Operating Expenses and Total Other Income Expense Net go up and down completely randomly.

Correlation Coefficient

0.46
Relationship DirectionPositive 
Relationship StrengthWeak

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Viking Therapeutics. It is also known as Viking Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Other Income Expense Net

Most indicators from Viking Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viking Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.Selling General Administrative is likely to rise to about 38.9 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (16.03).

Viking Therapeutics fundamental ratios Correlations

0.00.3-0.170.05-0.090.18-0.110.63-0.040.34-0.11-0.140.260.020.310.31-0.14-0.09-0.140.93-0.21-0.18-0.42-0.09-0.45
0.00.630.79-0.94-0.970.930.8-0.080.920.60.810.81-0.280.940.38-0.250.80.860.81-0.120.64-0.79-0.690.83-0.65
0.30.630.36-0.56-0.630.740.50.20.50.990.50.40.020.560.910.520.390.550.40.030.3-0.42-0.380.55-0.35
-0.170.790.36-0.87-0.820.670.87-0.260.960.310.881.0-0.360.860.17-0.281.00.871.0-0.230.88-0.83-0.70.62-0.66
0.05-0.94-0.56-0.870.96-0.87-0.780.14-0.96-0.51-0.79-0.890.35-1.0-0.30.24-0.88-0.83-0.880.15-0.650.740.64-0.640.59
-0.09-0.97-0.63-0.820.96-0.92-0.770.02-0.95-0.59-0.78-0.840.28-0.97-0.390.2-0.84-0.85-0.840.03-0.610.780.72-0.740.67
0.180.930.740.67-0.87-0.920.63-0.010.830.720.640.7-0.220.880.58-0.070.690.70.7-0.010.45-0.63-0.570.7-0.53
-0.110.80.50.87-0.78-0.770.63-0.180.850.441.00.87-0.390.740.23-0.260.860.990.87-0.160.93-0.9-0.770.81-0.74
0.63-0.080.2-0.260.140.02-0.01-0.18-0.150.29-0.18-0.240.64-0.10.190.3-0.24-0.16-0.240.58-0.26-0.03-0.26-0.08-0.23
-0.040.920.50.96-0.96-0.950.830.85-0.150.460.860.97-0.330.960.29-0.250.960.890.97-0.140.78-0.84-0.740.7-0.69
0.340.60.990.31-0.51-0.590.720.440.290.460.440.360.170.520.920.560.350.490.350.050.25-0.4-0.370.51-0.34
-0.110.810.50.88-0.79-0.780.641.0-0.180.860.440.88-0.390.760.23-0.260.870.990.88-0.160.93-0.91-0.780.81-0.74
-0.140.810.41.0-0.89-0.840.70.87-0.240.970.360.88-0.340.880.22-0.241.00.881.0-0.220.88-0.84-0.70.63-0.66
0.26-0.280.02-0.360.350.28-0.22-0.390.64-0.330.17-0.39-0.34-0.330.210.44-0.34-0.39-0.340.2-0.330.190.05-0.280.04
0.020.940.560.86-1.0-0.970.880.74-0.10.960.520.760.88-0.330.32-0.220.870.80.87-0.10.62-0.73-0.650.62-0.61
0.310.380.910.17-0.3-0.390.580.230.190.290.920.230.220.210.320.730.210.270.21-0.020.1-0.17-0.140.31-0.12
0.31-0.250.52-0.280.240.2-0.07-0.260.3-0.250.56-0.26-0.240.44-0.220.73-0.24-0.26-0.240.08-0.250.260.24-0.250.22
-0.140.80.391.0-0.88-0.840.690.86-0.240.960.350.871.0-0.340.870.21-0.240.871.0-0.220.87-0.83-0.70.61-0.66
-0.090.860.550.87-0.83-0.850.70.99-0.160.890.490.990.88-0.390.80.27-0.260.870.87-0.150.88-0.89-0.770.85-0.73
-0.140.810.41.0-0.88-0.840.70.87-0.240.970.350.881.0-0.340.870.21-0.241.00.87-0.220.88-0.84-0.70.63-0.66
0.93-0.120.03-0.230.150.03-0.01-0.160.58-0.140.05-0.16-0.220.2-0.1-0.020.08-0.22-0.15-0.22-0.22-0.16-0.41-0.16-0.46
-0.210.640.30.88-0.65-0.610.450.93-0.260.780.250.930.88-0.330.620.1-0.250.870.880.88-0.22-0.88-0.720.69-0.7
-0.18-0.79-0.42-0.830.740.78-0.63-0.9-0.03-0.84-0.4-0.91-0.840.19-0.73-0.170.26-0.83-0.89-0.84-0.16-0.880.96-0.770.94
-0.42-0.69-0.38-0.70.640.72-0.57-0.77-0.26-0.74-0.37-0.78-0.70.05-0.65-0.140.24-0.7-0.77-0.7-0.41-0.720.96-0.650.99
-0.090.830.550.62-0.64-0.740.70.81-0.080.70.510.810.63-0.280.620.31-0.250.610.850.63-0.160.69-0.77-0.65-0.61
-0.45-0.65-0.35-0.660.590.67-0.53-0.74-0.23-0.69-0.34-0.74-0.660.04-0.61-0.120.22-0.66-0.73-0.66-0.46-0.70.940.99-0.61
Click cells to compare fundamentals

Viking Therapeutics Account Relationship Matchups

Viking Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Other Current Liab4.0M7.5M7.3M12.8M11.0M11.5M
Total Current Liabilities6.8M12.1M8.8M21.9M19.1M10.4M
Total Stockholder Equity277.1M244.3M201.9M145.3M348.4M365.8M
Net Debt(7.7M)(28.8M)(26.3M)(35.1M)(54.3M)(51.5M)
Retained Earnings(128.7M)(168.2M)(223.2M)(292.0M)(377.9M)(359.0M)
Accounts Payable2.4M4.0M1.4M8.5M7.5M7.9M
Non Current Liabilities Total360K29K1.5M1.3M936K1.1M
Other Stockholder Equity405.8M412.6M425.6M438.5M726.8M763.1M
Total Liab7.1M12.2M8.8M23.2M20.1M11.3M
Total Assets284.3M256.5M210.7M168.5M368.5M386.9M
Cash8.4M29.1M26.4M36.6M55.5M58.3M
Non Current Assets Total755K398K134K1.5M1.3M755.8K
Non Currrent Assets Other157K77K109K71K139K132.1K
Cash And Short Term Investments275.6M248.4M202.1M155.5M362.1M380.2M
Common Stock Shares Outstanding72.0M72.6M77.2M76.8M94.3M50.8M
Liabilities And Stockholders Equity284.3M256.5M210.7M168.5M368.5M386.9M
Total Current Assets283.5M256.1M210.5M167.0M367.2M385.6M
Net Tangible Assets277.1M244.3M201.9M145.3M167.1M143.6M
Other Assets157K398K109K71K63.9K60.7K
Other Current Assets7.9M7.7M8.4M11.6M5.1M4.9M
Deferred Long Term Liab128K48K76K38K34.2K32.5K
Retained Earnings Total Equity(128.7M)(168.2M)(223.2M)(292.0M)(262.8M)(249.7M)
Short Term Investments267.3M219.3M175.7M118.9M306.6M171.0M
Capital Surpluse405.8M412.6M425.6M445.3M512.1M317.3M
Accumulated Other Comprehensive Income12K(54K)(549K)(1.1M)(389K)(408.5K)
Net Invested Capital277.1M244.3M201.9M145.3M348.4M240.7M
Net Working Capital276.7M244.0M201.8M145.1M348.1M239.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.